Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 24-year-old woman with type 1 diabetes mellitus is admitted to the intensive care unit with diabetic ketoacidosis. Initial laboratory studies show a blood glucose of 520520 mg/dL, an arterial pH of 7.127.12, an anion gap of 2222, and a serum potassium of 2.92.9 mEq/L. Arrange the following steps regarding her ongoing management, monitoring, and therapeutic transition in the correct chronological sequence.

  1. 1Administer rapid intravenous fluid resuscitation with 0.9%0.9\% normal saline.
  2. 2Administer intravenous potassium replacement and delay insulin therapy until serum potassium is ≥3.3\geq 3.3 mEq/L.
  3. 3Initiate a continuous intravenous regular insulin infusion to suppress ketogenesis.
  4. 4Add 5%5\% dextrose to the intravenous fluids when blood glucose decreases to 200−250200-250 mg/dL.
  5. 5Transition to a subcutaneous basal-bolus insulin regimen once the anion gap normalizes and the patient can tolerate oral intake.

Answer

The correct sequence for managing, monitoring, and transitioning therapy in diabetic ketoacidosis with severe hypokalemia is: 1) Initial fluid resuscitation, 2) Potassium replacement while holding insulin, 3) Intravenous insulin initiation, 4) Addition of dextrose to fluids, and 5) Transition to subcutaneous insulin.
The management of diabetic ketoacidosis requires a precise sequence of interventions based on continuous monitoring. First, intravascular volume must be restored with normal saline to improve tissue perfusion. Second, because total body potassium is depleted and insulin drives potassium intracellularly, serum potassium must be corrected to at least 3.3 mEq/L before initiating insulin to prevent fatal arrhythmias. Third, once potassium is safe, continuous intravenous regular insulin is started to suppress ketogenesis and resolve the acidosis. Fourth, because blood glucose typically normalizes faster than the ketoacidosis resolves, 5% dextrose is added to the intravenous fluids when glucose reaches 200-250 mg/dL; this prevents hypoglycemia while allowing the insulin infusion to continue. Finally, once serial monitoring shows a closed anion gap and the patient is tolerating oral intake, therapy is safely de-escalated to a subcutaneous basal-bolus insulin regimen.

Step-by-Step Solution

1
Identify the immediate need for intravascular volume expansion.
Administer 0.9% normal saline.
Patients with DKA have profound osmotic diuresis leading to severe dehydration; restoring perfusion is the priority.
2
Assess the initial serum potassium level prior to insulin administration.
Hold insulin and replace potassium intravenously.
The patient's potassium is critically low at 2.9 mEq/L. Insulin drives potassium intracellularly; giving it now would cause life-threatening hypokalemia.
3
Evaluate potassium status to determine when it is safe to start insulin.
Initiate continuous intravenous regular insulin infusion.
Once potassium is replenished to at least 3.3 mEq/L, insulin is required to halt lipolysis and resolve the anion gap acidosis.
4
Monitor serial blood glucose levels during the continuous insulin infusion.
Add 5% dextrose to the IV fluids.
Glucose falls faster than ketones clear. Dextrose must be added when glucose reaches 200-250 mg/dL to allow continued insulin administration without causing hypoglycemia.
5
Monitor serial basic metabolic panels to evaluate the anion gap.
Transition to a subcutaneous insulin regimen.
Once the anion gap closes (indicating resolution of ketoacidosis) and the patient can tolerate oral intake, intravenous therapy can be safely de-escalated.

Key Concept

Successful management and monitoring of diabetic ketoacidosis requires strict sequential interventions: volume repletion, potassium correction prior to insulin initiation, glucose monitoring to determine dextrose addition, and anion gap monitoring to determine safe transition to subcutaneous insulin.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic